Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1018-H5 Pandemic Influenza Vaccine in Adults
NCT07496450Phase 3Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Mar 2026
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of mRNA-1018 in influenza, sponsored by Moderna Inc. Started Mar 2026; status: active, not recruiting.
02
Drugs
mRNA-1018
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07496450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07496450.